Oscar Health is experiencing a dramatic growth inflection, with revenue surging 70.4% YoY to $4.9B in 2026Q2 and achieving a record combined ratio of 84.8% in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.49+440.7% vs -$0.14 | $5.1B+9.5% vs $4.7B |
Q3 2026 Aug 6, 2026 | $1.10+173.0% vs $0.40 | $4.8B+1.3% vs $4.7B |
Q2 2026 May 6, 2026 | $2.07+71.1% vs $1.21 | $4.6B-6.4% vs $4.9B |
Q1 2026 Feb 10, 2026 | -$1.24-34.6% vs -$0.92 | $2.7B-12.1% vs $3.1B |
Oscar Health raises its 2026 earnings outlook as improving medical costs and operating efficiencies boost margins, while expansion fuels 2027 growth ambitions.
MDB, INGM, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 6, 2026.
Oscar Health, Inc. ( OSCR ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Mark Bertolini - CEO & Director Richard Blackley - Chief Financial Officer Chris Potochar - Vice President of Treasury & Investor Relations Conference Call Participants Andrew Mok - Barclays Bank PLC, Research Division Jessica Tassan - Piper Sandler & Co., Research Division Parker Snure - Raymond James & Associates, Inc., Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Jonathan Yong - UBS Investment Bank, Research Division Hua Ha - Robert W. Baird & Co. Incorporated, Research Division Joaquin Eduardo Martinez - BofA Securities, Research Division Presentation Mark Bertolini CEO & Director [Audio Gap] address consumer needs, including opportunities created by competitor exits.
HCA posted its biggest one-day jump in four years before a single law changed. Wall Street is pricing in relief that needs Congress, a presidential signature, and a December funding fight to survive.
Benchmark OSCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Oscar Health, Inc. (OSCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $30.65 | $7.95B | 12.41 | 27.5% | 4.9% | 49.39% | — | |
| $4.82 | $2.5B | 216.14 | 40.34% | 0.45% | 3.52% | — | |
| $7.34 | $1.52B | 52.92 | 46.06% | 0.59% | 12.46% | — | |
| $107.28 | $37.48B | 8.37 | 14.27% | 23.19% | 18.35% | 0.02% | |
| $14.48 | $2.18B | -4.03 | — | — | -2271.87% | — | |
| $0.57 | $23.97M | -2.53 | — | — | -106.96% | — |
Oscar Health, Inc. (OSCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Oscar Health, Inc. (OSCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 9, 2026·SEC
Jun 8, 2026·SEC
Get notified when OSCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oscar Health, Inc. (OSCR) stock FAQ — growth, dividends, profitability & financials explained
Oscar Health, Inc. (OSCR) grew revenue by 54.8% over the trailing twelve months, compared with the twelve months before.
Yes. Oscar Health, Inc. (OSCR) earned $855.5M in net income over the trailing twelve months (a 4.9% net margin).
Oscar Health, Inc. (OSCR) had a return on equity (ROE) of 49.4% over the trailing twelve months. That is well above the market's typical 10-15%.
Oscar Health, Inc. (OSCR) has a combined ratio of 103.4%. A ratio above 100% means claims and expenses exceed premiums.
